RhumbLine Advisers’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

RhumbLine Advisers’s Portfolio SIOX Stock Details SIOX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-3,462	Closed	-$37K	–	2939
2018 Q1	$37K	Buy	3,462 +13	+0.4%	+$209	﹤0.01%	2803
2017 Q4	$145K	Sell	3,449 -690	-17%	-$31K	﹤0.01%	2716
2017 Q3	$228K	Buy	4,139 +75	+2%	+$12.7K	﹤0.01%	2671
2017 Q2	$754K	Buy	4,064 +841	+26%	+$147K	﹤0.01%	2098
2017 Q1	$385K	Buy	3,223 +114	+4%	+$11.9K	﹤0.01%	2379
2016 Q4	$309K	Buy	3,109 +363	+13%	+$38.2K	﹤0.01%	2482
2016 Q3	$308K	Buy	2,746 +62	+2%	+$7.44K	﹤0.01%	2476
2016 Q2	$276K	Buy	2,684 +1,025	+62%	+$102K	﹤0.01%	2579
2016 Q1	$152K	Buy	1,659 +96	+6%	+$10.2K	﹤0.01%	2818
2015 Q4	$225K	Buy	+1,563	New	+$203K	﹤0.01%	2739

Other funds holding SIOX

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

MWNA

Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RhumbLine Advisers's SIOX Position: Q2 2018 in Review

RhumbLine Advisers sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q2 2018, closing a stake of 3,462 shares — an estimated $37K sold.

RhumbLine Advisers first reported a position in SIOX in Q4 2015 and held it in 10 quarters. The position peaked at $754K in Q2 2017. 71 funds tracked by Wall St. Rank hold SIOX as of Q2 2018.

RhumbLine Advisers reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
RhumbLine Advisers sold 3,462 Sio Gene Therapies Inc. Common Stock shares in Q2 2018, an estimated $37K.
RhumbLine Advisers first reported a position in Sio Gene Therapies Inc. Common Stock in Q4 2015 and held it in 10 quarters.
RhumbLine Advisers's Sio Gene Therapies Inc. Common Stock position peaked at $754K in Q2 2017.
71 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q2 2018.

Based on RhumbLine Advisers's 13F filing for Q2 2018, filed 6 Aug 2018.